News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nektar Therapeutics (CA) (NKTR) Stands to Gain $25 Million From AstraZeneca PLC (AZN) Filing


8/29/2013 8:09:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nektar Therapeutics Inc. will get $25 million from AstraZeneca plc if a European regulatory filing for an anti-constipation drug is accepted. San Francisco-based Nektar (NASDAQ: NKTR) received $125 million upfront when it inked a 2009 licensing deal with AstraZeneca for naloxegol, which is aimed at relieving constipation caused by pain-killing opioid drugs. But if the European Medicines Agency accepts AstraZeneca's application, which typically happens within 30 days, Nektar would receive the additional $25 million payout.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES